Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool September 8, 2004 Charly Travers	Will a Clinical Trial Database Help Investors? While this development is certainly good news for patients and physicians, the impact on investors may be minimal, depending upon the type of data that will be released.
The Motley Fool September 5, 2007 Billy Fisher	Lilly's Pipeline Continues to Produce Another schizophrenia drug from the company shows promise in a clinical trial, prompting the company to plan additional trials. This is the latest good news in what has been a good year for Lilly.
Pharmaceutical Executive October 1, 2005 Lisa Grimes	Clear Road Ahead An industry standard for publicizing clinical-trial results is a ways off. But pharma's openness to more transparent procedures is moving things in the right direction.
The Motley Fool May 11, 2010 Ryan McBride	Clinical Data Seeks to Challenge Lilly, Pfizer in Antidepressant Market The tiny drug developer has no problem going up against bigger rivals.
Chemistry World September 5, 2014 Emma Stoye	Servier to appear in adverts over lack of transparency European pharma group Servier Laboratories is to appear in adverts for breaching the Association of the British Pharma Industry code of practice by failing to publish clinical trial results.
Bio-IT World February 2006 Mark D. Uehling	Pharma's Mixed Response to Trials Database A late December New England Journal of Medicine article detailed Big Pharma's response to mandatory registration of clinical trials. Here are some highlights.
The Motley Fool December 14, 2010 Brian Orelli	Another Mishap for a Drugmaker That Can't Afford It Eli Lilly puts cancer drug tasisulam on a clinical hold.
Information Today October 4, 2004 Susanne Bjorner	A Tough Test for PhRMA's New Clinical Study Results Database The announcement the day before of a worldwide withdrawal of Merck & Co.'s popular arthritis and acute pain medication Vioxx, created a high-bar test that shows the holes in the new database concept.
The Motley Fool January 31, 2011 Brian Orelli	Better Buy: Amarin or Clinical Data? A battle of the takeover targets.
Chemistry World February 7, 2013 Maria Burke	GSK commits to AllTrials data disclosure GlaxoSmithKline has become the first pharmaceutical company to sign up to a high-profile campaign to make detailed data on all clinical trials available to the public.
The Motley Fool December 22, 2009 Brian Orelli	Some Incyte Into Why These Drugs Rock Eli Lilly jumps on the oral-drug-for-rheumatoid-arthritis bandwagon.
The Motley Fool November 13, 2009 Brian Orelli	Questioning Pfizer's Integrity Pfizer's epilepsy drug Neurontin has had generic competition for a few years, but it's still plaguing the pharmaceutical giant.
The Motley Fool March 24, 2005 Brian Gorman	Eli Lilly Turns to Japan The company's move to focus more resources on Japan makes good sense.
The Motley Fool March 29, 2010 Brian Orelli	Look for Companies That Strike First Head-to-head trials, whether they're run by companies or by third parties, can be scary. But the way to make big money is by selling drugs that offer superior benefits, so investors should welcome the onslaught of upcoming comparative trial data.
The Motley Fool July 27, 2007 Tom Taulli	A New Phase for Phase Forward Phase Forward wins a multi-million dollar contract for its clinical trial software; this infusion of cash provides even more resources for pursuing more growth.
The Motley Fool January 14, 2011 Brian Orelli	Don't Have a Stroke Over Merck's Heart Drug Welcome to pharma investing.
The Motley Fool September 25, 2008 Brian Lawler	Eli Lilly's Dose of Disclosure The pharmaceutical pledges public reports of its dealings with doctors.
The Motley Fool December 29, 2006 Brian Lawler	Is Threshold on the Verge of Success? Shares of Threshold Pharmaceuticals were the second-best performer on the market yesterday, up 28% as a result of positive phase 2 clinical trial results for its lead drug, glufosfamide.
The Motley Fool March 4, 2011 Brian Orelli	Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors.
Pharmaceutical Executive September 1, 2008 Melanie North	Publish or Perish FDAAA means that companies need to register clinical trials; and not only for publication planning.
The Motley Fool November 30, 2004 Brian Gorman	Glaxo Targeted for Kids' Trials Criticism of Glaxo could benefit investors in the long run: Although these companies will continue to evolve, their role as dominant players in drug development seems secure. Those investors willing to dip a toe in now could reap rich rewards.
Managed Care July 2005 Martin Sipkoff	Support Grows for Establishing National Clinical Trial Registry Stakeholders are pushing for a national clinical trial registry, and efforts by UnitedHealth Group are in the forefront. Medical journals are setting hard and fast rules.
Chemistry World August 7, 2013 Emma Stoye	AllTrials releases plan for clinical trial reporting The organizations behind AllTrials, a public campaign calling for detailed information on clinical trials to be publically available, have put together a detailed plan on how to achieve clinical trial reporting on a global scale.
Chemistry World February 26, 2008 James Mitchell Crow	Q and A: Do Antidepressants Work? A widely-reported analysis of clinical trial data for Prozac and related antidepressant drugs has claimed that the medicines work little better than chemically-inactive placebos in all but the most severely depressed patients.
The Motley Fool April 16, 2010 Brian Orelli	It'll Be a Blockbuster! High Fives All Around, Right? Sanofi-aventis releases top-line data for its phase 3 diabetes drug candidate, lixisenatide. The trial was a success, but don't pencil it in as a blockbuster just yet.
Bio-IT World July 2005 Kevin Davies	Trial Registries on Trial A group of influential editors from some of the world's boutique medical journals begin enforcing a new policy that would bar drug companies from publishing clinical trial data unless those trials are registered in a suitable public database.
The Motley Fool December 29, 2006 Brian Lawler	Lilly's Patents Stay in Bloom Even with upcoming patent expiries, Lilly isn't in nearly the same desperate situation that some of its large-cap pharma peers will be dealing with in the upcoming years. Investors, take note.
Pharmaceutical Executive November 1, 2006	Unraveling the eSource Industry-wide standards for electronic patient data have long felt like buried treasure. Companies today are getting closer - by way of a tangled map.
The Motley Fool September 30, 2004 W. D. Crotty	Merck Chokes Back Vioxx The $2.3 billion arthritis drug is withdrawn from the market after clinical studies point to dangerous side-effects. Despite the bad news, Merck's big dividend payouts don't appear to be in jeopardy at the moment.
The Motley Fool December 10, 2009 Brian Orelli	A Tale of Two Lillys It was the best of times, it was the worst of times. Dickens could have been talking about Eli Lilly which has a tale of two cities all on its own.
The Motley Fool March 1, 2007 Brian Lawler	Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works.
Chemistry World November 12, 2013 Dinsa Sachan	Rough patch for India's clinical trial industry The Indian clinical trial industry is beset by uncertainty. Campaigners have petitioned the courts claiming that drug companies are exploiting poor people and this has led to more than 100 trials being put on hold.
The Motley Fool July 30, 2009 Robert Steyer	Covance Advances Covance latest results produce more optimism than did some of its contract research peers.
Bio-IT World March 8, 2005 Mark D. Uehling	Is That a Target on Her Back? Q&A with Deborah Zarin, head of ClinicalTrials.gov, the matchmaking Web site for patients seeking to participate in federally sponsored clinical trials.
The Motley Fool January 31, 2007 Brian Lawler	Lilly Floats Atop Rivals The large-cap pharma posts slow, steady growth. Investors, take note.
The Motley Fool April 27, 2006 Stephen D. Simpson	A Sluggish Bristol-Myers Squibb Generic erosion is going to chew away revenue and profits. Investors, at today's prices, there are just too many other better ideas to go after.
The Motley Fool September 30, 2008 Brian Orelli	Pharma, Cash, and You Pharma's been saving for a rainy day, and there's a thunderstorm outside.
Bio-IT World December 15, 2004 Kevin Davies	Patients Before Profits? After the Vioxx disaster, Pharma needs to reassure patients that they come first.
Bio-IT World January 21, 2005	How IT Can Decrease Time-to-Market in Clinical Trials Pharma manufacturers can learn from their industrial counterparts: Integrating systems can accelerate product delivery.
Information Today July 2, 2013	Thomson Reuters Offers Clinical Trial Intelligence Solutions These solutions improve clinical trials, speed up product development and release, and help professionals strengthen portfolios and R&D strategy.
The Motley Fool August 4, 2010 Ryan McBride	How Eli Lilly Let a Billion-Dollar Molecule Slip Away, and Make a Fortune for Vertex The remains of Lilly's partnership with Vertex Pharmaceuticals.
The Motley Fool December 13, 2005 Rich Duprey	Merck's Bitter Pill The first federal Vioxx trial ends with a deadlocked jury, but that's not necessarily good news for the drugmaker, or investors.
The Motley Fool January 20, 2011 Brian Orelli	This Stock Is No Dreamboat The FDA is not kind to MannKind.
The Motley Fool April 17, 2007 Ryan Fuhrmann	Clean Bill of Health at Eli Lilly Lilly recorded another solid quarter, but its valuation is a little rich.
The Motley Fool April 10, 2006 Rich Duprey	Merck Splits the Difference The pharmaceutical wins one, loses one in New Jersey Vioxx trials. Investors should expect to see more losses.
Bio-IT World August 2005 Ellen H. Julian	Tech Expertise Singles Out Outsourcers Biopharmaceutical companies are flocking to consultants, outsourcers, and staffing firms to help with discrete clinical trial processes to gain access to advanced technologies and reduce the drain on already-scarce IT resources.
The Motley Fool November 18, 2009 Brian Orelli	VIVUS Gets a Spark A new erectile-dysfunction drug shows promise.
Bio-IT World April 2006 Mark D. Uehling	Debating Clinical Registries and Databases The pharmaceutical industry has been forced by medical journal editors and Congress to make public more data about clinical trials. Registries are here, most people are used to them, and they're not going away. But can the industry do registries and databases better?
Pharmaceutical Executive June 1, 2007 Dinh Nguyen	Clinical Trials Under Scrutiny Over the last few years, there has been a growing number of instances of misconduct in clinical research.
The Motley Fool February 22, 2011 Ryan McBride	Forest Labs Snaps Up Clinical Data This deal is the latest proof that drug developers with FDA-approved treatments remain hot buyout targets in a pharma industry that is starved for new products to replace brand-name drugs.